Holl-Wieden A, Beer M, Marx A, Bonfig R, Tappe D, Girschick H J
Children's Hospital, Section of Pediatric Rheumatology, Immunology and Infectious Diseases, University of Wuerzburg, Wuerzburg, Germany.
Rheumatol Int. 2008 Jun;28(8):819-22. doi: 10.1007/s00296-008-0521-z. Epub 2008 Jan 12.
Etanercept, a tumor necrosis factor (TNF) receptor alpha antagonist is licensed for the treatment in patients affected by polyarticular juvenile idiopathic arthritis, who do not tolerate or had an inadequate response to methotrexate. Infections related to immunosuppression by etanercept are of major concern. We report on a 17-year-old boy with enthesitis-related arthritis who developed a major infection of an urachal cyst 18 months after initiation of etanercept therapy, which required surgery. The urachus had not been symptomatic before.
依那西普是一种肿瘤坏死因子（TNF）受体α拮抗剂，已获许可用于治疗多关节型幼年特发性关节炎且对甲氨蝶呤不耐受或反应不佳的患者。与依那西普免疫抑制相关的感染是主要关注点。我们报告了一名17岁患有附着点炎相关关节炎的男孩，在开始依那西普治疗18个月后发生脐尿管囊肿严重感染，需要进行手术。脐尿管在此之前并无症状。
